Form 4: Lisata Therapeutics Executive Kristen K. Buck Reports Stock Transactions

EVP, R&D and CMO of Lisata Therapeutics, Kristen K. Buck, reports acquisition of 15,000 shares and disposition of 6,363 shares for tax liabilities.

Summary

• On October 1, 2024, Kristen K. Buck, EVP, R&D and CMO of Lisata Therapeutics, acquired 15,000 shares of common stock at a price of $2.93.
• These shares were performance-based stock units that vested in full on the same day.
• Buck also disposed of 6,363 shares of common stock at $2.93 to cover tax liabilities related to the vesting of the performance-based stock units.
• Following these transactions, Buck beneficially owns 62,672 shares of Lisata Therapeutics stock, including 30,325 unvested restricted shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction report. The vesting of performance-based units is mildly positive, but the sale for tax purposes is neutral.

Positives

• The vesting of performance-based stock units suggests that performance criteria were met, which could be viewed positively.

Negatives

• The sale of shares to cover tax liabilities could be seen as a minor negative, although it's a common practice.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, as required by the SEC. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.

Key Dates